Search company, investor...


Founded Year



Growth Equity | Dead

Total Raised


Last Raised


About Exonet

Developer of a B2B platform bringing together actors in the pharmaceutical industry. The company's platforms enables pharmacies to place orders directly in their suppliers' systems and allows laboratories to target their marketing on their end-users and perform push/pull marketing operations. The company also develops Internet, Intranet and Extranet systems to offer complete e-business solutions for the pharmaceutical industry. Additionally, the company has introduces a B2C marketplace for pharmaceutical products.

Headquarters Location

26, rue Anatole France

Levallois-Perret, 92532,


33 1 47 15 24 70

Missing: Exonet's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Exonet's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Exonet News

Using cameras and AI to help exoskeletons adapt to their environment

Mar 15, 2021

Researchers at Canada’s University of Waterloo are showcasing work with prosthesis and exoskeletons that utilizes cameras and AI to deliver more natural human movement. The ExoNet project leverages video captured by wearable camera, run through deep learning AI, in order to mimic how humans adapt and adjust movements based on their environment. The project is an attempt to create more natural locomotion on the fly than is currently offered through systems with connected smartphone apps or other external controllers. “That can be inconvenient and cognitively demanding,” Waterloo PhD candidate Brokoslaw Laschowski said in a release tied to the research. “Every time you want to perform a new locomotor activity, you have to stop, take out your smartphone and select the desired mode.” The research highlighted primarily focuses on robotic exoskeletons, which are being developed by a number of different companies to help assist people with impaired mobility. The hope here is that the ExoNet system could eventually replace the need for external control by the wearer, in order to create more natural locomotion. Of course, there’s still a lot of work to be done. Naturally, the system is easier to navigate on flat terrain. Next steps would involve adapting it to environments that can give those with limited mobility some difficult, including stairs and other obstacles. A final version of the system would be able to anticipate and adapt accordingly. “Our control approach wouldn’t necessarily require human thought,” Laschowski adds. “Similar to autonomous cars that drive themselves, we’re designing autonomous exoskeletons that walk for themselves.” There are other challenges here, as well. Batteries are an issue, for one. The team is looking to improve longevity by experimenting with a system that can recharge with the wearer’s movement.

Exonet Frequently Asked Questions (FAQ)

  • When was Exonet founded?

    Exonet was founded in 1997.

  • Where is Exonet's headquarters?

    Exonet's headquarters is located at 26, rue Anatole France, Levallois-Perret.

  • What is Exonet's latest funding round?

    Exonet's latest funding round is Growth Equity.

  • How much did Exonet raise?

    Exonet raised a total of $2.58M.

  • Who are the investors of Exonet?

    Investors of Exonet include Chausson Finance and BNP Paribas Private Equity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.